OverviewSuggest Edit

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, COVID-19, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

TypePublic
Founded1987
HQFoster City, CA, US
Websitegilead.com
Employee Ratings3.8
Overall CultureB

Latest Updates

Employees (est.) (Dec 2020)13,600(+16%)
Job Openings840
Revenue (FY, 2020)$24.7 B(+10%)
Share Price (Sept 2021)$70.4
Cybersecurity ratingDMore

Key People/Management at Gilead Sciences

Daniel O’Day

Daniel O’Day

Chairman and Chief Executive Officer
Andrew Dickinson

Andrew Dickinson

Chief Financial Officer
Flavius Martin

Flavius Martin

Executive Vice President, Research
Jyoti Mehra

Jyoti Mehra

Executive Vice President, Human Resources
Johanna Mercier

Johanna Mercier

Chief Commercial Officer
Merdad Parsey

Merdad Parsey

Chief Medical Officer
Show more

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 45 other locations
Foster City, CA, US (HQ)
333 Lakeside Dr
El Segundo, CA, US
2355 Utah Ave
Emeryville, CA, US
5858 Horton St #240
Miami, FL, US
5200 Blue Lagoon Dr #450
Morris Plains, NJ, US
300 The American Rd
Oceanside, CA, US
4049 Avenida De La Plata
Show all (49)

Gilead Sciences Financials and Metrics

Gilead Sciences Revenue

Embed Graph
View revenue for all periods
Gilead Sciences's revenue was reported to be $24.69 b in FY, 2020 which is a 10% increase from the previous period.
USD

Revenue (Q1, 2021)

6.4b

Gross profit (Q1, 2021)

5.1b

Gross profit margin (Q1, 2021), %

78.8%

Net income (Q1, 2021)

1.7b

EBIT (Q1, 2021)

2.9b

Market capitalization (14-Sept-2021)

88.4b

Closing stock price (14-Sept-2021)

70.4

Cash (31-Mar-2021)

4.1b

EV

114.5b
Gilead Sciences's current market capitalization is $88.4 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

22.1b22.4b24.7b

Revenue growth, %

(15%)1%10%

Cost of goods sold

4.9b4.7b4.6b

Gross profit

17.3b17.8b20.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

5.3b5.7b5.6b5.5b5.1b6.6b6.4b

Cost of goods sold

957.0m1.0b1.0b969.0m1.1b1.1b1.4b

Gross profit

4.3b4.7b4.6b4.6b4.1b5.4b5.1b

Gross profit Margin, %

82%82%82%83%79%83%79%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

17.9b11.6b6.0b

Accounts Receivable

3.3b3.6b4.9b

Prepaid Expenses

1.6b1.4b2.0b

Inventories

814.0m922.0m1.7b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

16.9b11.2b9.5b10.1b6.7b12.9b4.1b

Accounts Receivable

3.3b3.4b3.3b3.9b3.2b3.9b3.9b

Prepaid Expenses

1.9b2.3b1.3b1.3b1.5b2.0b1.9b

Inventories

898.0m884.0m882.0m986.0m1.1b1.0b1.8b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

5.5b5.4b89.0m

Depreciation and Amortization

1.4b1.4b1.5b

Inventories

(310.0m)(95.0m)(195.0m)

Accounts Payable

(39.0m)(61.0m)80.0m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

2.0b3.8b2.7b1.5b(1.8b)(1.5b)1.7b

Depreciation and Amortization

359.0m707.0m1.1b349.0m698.0m1.1b473.0m

Inventories

(15.0m)(12.0m)(35.0m)15.0m(22.0m)(48.0m)(69.0m)

Accounts Payable

(201.0m)(166.0m)(142.0m)(109.0m)(113.0m)(134.0m)(253.0m)
USDFY, 2018

EV/EBIT

10.7 x

EV/CFO

10.4 x

Revenue/Employee

2.2m

Debt/Equity

1.1 x

Debt/Assets

0.4 x

Financial Leverage

3 x

P/E Ratio

15.0
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019Sep, 2020Dec, 2020FY, 2020

Countries

3035353535

Patents (US)

642650

Phase III Trials Products

4941278

Products

2527242420
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
MYRDecember 10, 2020€1.15 b
ImmunomedicsSeptember 13, 2020$21 b
Forty SevenMarch 21, 2020$4.9 b
Cell Design LabsDecember 07, 2017$567 m
Kite PharmaAugust 28, 2017$11.9 b
Nimbus ApolloMay 17, 2016
EpitherapeuticsMay 06, 2015$65 m
Phenex PharmaceuticalsJanuary 06, 2015$470 m
YM BioSciencesFebruary 08, 2013$487.6 m
PharmassetNovember 21, 2011$11 b
Show more

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by business segment: 98.6% from Product Sales and 1.4% from Other

Gilead Sciences revenue breakdown by geographic segment: 16.7% from Europe, 73.8% from United States and 9.5% from Other

Show all human capital metrics

Gilead Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

D

62/100

SecurityScorecard logo

Gilead Sciences Online and Social Media Presence

Embed Graph

Gilead Sciences Company Culture

  • Overall Culture

    B

    69/100

  • CEO Rating

    B-

    69/100

  • Compensation

    A+

    83/100

  • Diversity

    B

    70/100

Learn more on Comparably

Gilead Sciences News and Updates

Worldwide Biotechnology Industry to 2026 - Featuring Amgen, Gilead Sciences and Biogen Among Others

Dublin, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The "Global Biotechnology Market, By Application (Bio-Pharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture), By End User (Biotechnology & Pharmaceutical Companies, Academic Institutions, Others), By Region, Competition Forecast & Opportunities…

: Rand Paul reveals his wife invested in remdesivir parent company Gilead Sciences at the start of the pandemic

Congressional members are required to disclose stock trades within 45 days. Rand Paul’s reporting came 16 months late.

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer

MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, tod…

Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV). Findings from the Phase 3 study support the safety and e…

Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China

Kite, a Gilead Company, announced that Fosun Kite Biotechnology Co., Ltd., a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, has received approval from the China National Medical Products Administration (NMPA) for axicabtagene ciloleucel for the treatment of adult pati…

Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company’s liver disease programs will be presented at The International Liver Congress™ 2021 (ILC) taking place from June 23-26. The breadth of data reflects Gilead’s continued commitment to liver disease, incl…
Show more

Gilead Sciences Frequently Asked Questions

  • When was Gilead Sciences founded?

    Gilead Sciences was founded in 1987.

  • Who are Gilead Sciences key executives?

    Gilead Sciences's key executives are Daniel O’Day, Andrew Dickinson and Flavius Martin.

  • How many employees does Gilead Sciences have?

    Gilead Sciences has 13,600 employees.

  • What is Gilead Sciences revenue?

    Latest Gilead Sciences annual revenue is $24.7 b.

  • What is Gilead Sciences revenue per employee?

    Latest Gilead Sciences revenue per employee is $1.8 m.

  • Who are Gilead Sciences competitors?

    Competitors of Gilead Sciences include Novo Nordisk, Catalent and Biogen.

  • Where is Gilead Sciences headquarters?

    Gilead Sciences headquarters is located at 333 Lakeside Dr, Foster City.

  • Where are Gilead Sciences offices?

    Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 45 other locations.

  • How many offices does Gilead Sciences have?

    Gilead Sciences has 49 offices.